Rubius Therapeutics | 15-12G:终止注册
Rubius Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-FMR LLC(0.329%),Abigail P. Johnson(0.329%)
Rubius Therapeutics | 8-K:重大事件
Rubius Therapeutics | 25:注销已到期、已赎回、已兑付证券的通知
Rubius Therapeutics | DEF 14A:股东委托书决议
Rubius Therapeutics | 8-K:重大事件
Rubius Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Baillie Gifford & Co (Scottish partnership)(0%)
Rubius Therapeutics | PRER14A:初步修订代理权征集材料
Rubius Therapeutics | 4:持股变动声明
Rubius Therapeutics | PRE 14A:并购重组委托声明
Rubius Therapeutics | 10-K:2022财年年报
Rubius Therapeutics | S-8 POS:员工福利计划证券登记(修正)
Rubius Therapeutics | S-8 POS:员工福利计划证券登记(修正)
Rubius Therapeutics | S-8 POS:员工福利计划证券登记(修正)
Rubius Therapeutics | S-8 POS:员工福利计划证券登记(修正)
Rubius Therapeutics | S-8 POS:员工福利计划证券登记(修正)
Rubius Therapeutics | RW:注册提款请求
Rubius Therapeutics | 8-K:重大事件
Rubius Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Noubar B. Afeyan, Ph.D.(42.7%),Flagship Ventures Fund IV General Partner LLC(26.8%)等
Rubius Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Abigail P. Johnson(13.694%),FMR LLC(13.694%)
暂无数据
暂无数据